NYSE$USNA
USANA Health Sciences Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Net sales and diluted EPS decreased due to challenging operating environment and difficult prior-year comparison.
USANA Health Sciences reported third quarter results modestly ahead of preliminary outlook. Net sales were $274.4 million, a decrease compared to $298.5 million in the prior year. Diluted EPS were $1.36, down from $1.44 in the third quarter of 2020. The company reiterated its fiscal 2021 net sales and diluted EPS outlook and expects to generate approximately $130 million of free cash flow in fiscal 2021.
- Third quarter net sales were $274.4 million, compared to $298.5 million in the prior year.
- Third quarter diluted EPS was $1.36, versus $1.44 in the third quarter of 2020.
- Company ended the quarter with $249 million in cash and cash equivalents and no debt after repurchasing 523,000 shares for $50 million.
- The company reiterated its net sales and earnings per share outlook for fiscal year 2021.
Headline financials
Revenue & EPS history
USANA · Revenue · Quarterly
$274M
Forward guidance
The Company is reiterating its net sales and earnings per share outlook for fiscal year 2021, which was provided on September 16, 2021. Fiscal Year 2021 Outlook Range Consolidated Net Sales $1.18 - $1.20 billion Diluted EPS $5.80 - $6.00
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+2.3%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+1.6%
Avg return
30 days after
58%
37 / 64 earnings
Positive
+39.2%
Q2 2015
Best reaction
-24.1%
Q4 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.3% | -9.7% | -7.0% | |
| Q3 2025 | -1.6% | -2.8% | -6.0% | |
| Q2 2025 | +4.1% | +0.8% | +1.5% | |
| Q1 2025 | +4.9% | +13.6% | +21.4% | |
| Q4 2024 | +3.9% | -6.2% | -13.1% | |
| Q3 2024 | +4.4% | +5.0% | +12.3% | |
| Q2 2024 | -3.7% | -7.7% | -14.6% | |
| Q1 2024 | +6.0% | +6.0% | +8.7% | |
| Q4 2023 | +7.1% | +9.6% | +4.6% | |
| Q3 2023 | -16.7% | -17.7% | -13.8% | |
| Q2 2023 | +6.5% | +2.1% | -0.3% | |
| Q1 2023 | +4.9% | +2.5% | -4.4% | |
| Q4 2022 | +4.7% | +4.0% | +2.4% | |
| Q3 2022 | -0.2% | -3.0% | -6.5% | |
| Q2 2022 | +1.1% | +1.4% | -0.5% | |
| Q1 2022 | -3.6% | -2.6% | -10.4% | |
| Q4 2021 | -8.4% | -5.2% | -10.1% | |
| Q3 2021 | -8.0% | -3.4% | +1.3% | |
| Q2 2021 | -2.3% | -6.8% | -6.9% | |
| Q1 2021 | -7.7% | -6.4% | +9.4% | |
| Q4 2020 | +15.7% | +6.3% | +16.4% | |
| Q3 2020 | +5.1% | +10.7% | -3.5% | |
| Q2 2020 | -6.4% | -12.4% | -8.8% | |
| Q1 2020 | +17.5% | +25.2% | +23.8% | |
| Q4 2019 | +25.3% | +28.1% | +15.7% | |
| Q3 2019 | +11.5% | +4.8% | +1.8% | |
| Q2 2019 | +0.3% | +6.1% | +5.7% | |
| Q1 2019 | +9.4% | +2.2% | -12.9% | |
| Q4 2018 | -11.4% | -6.5% | -18.1% | |
| Q3 2018 | +3.5% | +2.7% | +13.0% | |
| Q2 2018 | +23.9% | +18.9% | +19.0% | |
| Q1 2018 | +11.6% | +10.3% | +22.2% | |
| Q4 2017 | +5.6% | +7.0% | +14.4% | |
| Q3 2017 | +12.5% | +9.7% | +10.1% | |
| Q2 2017 | -10.0% | -11.2% | -7.5% | |
| Q1 2017 | +6.5% | +13.4% | +16.4% | |
| Q4 2016 | -11.6% | -8.9% | -8.9% | |
| Q3 2016 | -8.2% | -11.5% | -13.6% | |
| Q2 2016 | +11.6% | +8.2% | +8.4% | |
| Q1 2016 | +6.2% | — | — | |
| Q4 2015 | -24.1% | — | — | |
| Q3 2015 | -11.6% | — | — | |
| Q2 2015 | +39.2% | — | — | |
| Q1 2015 | +19.2% | — | — | |
| Q4 2014 | -6.6% | — | — | |
| Q3 2014 | +26.5% | — | — | |
| Q2 2014 | -7.8% | — | — | |
| Q1 2014 | -15.2% | — | — | |
| Q4 2013 | +18.8% | — | — | |
| Q3 2013 | -9.6% | — | — | |
| Q2 2013 | -13.3% | — | — | |
| Q1 2013 | +8.1% | — | — | |
| Q4 2012 | +5.8% | — | — | |
| Q3 2012 | +1.7% | — | — | |
| Q2 2012 | +5.4% | — | — | |
| Q1 2012 | +2.0% | — | — | |
| Q4 2010 | -4.2% | — | — | |
| Q4 2011 | -4.2% | — | — | |
| Q3 2011 | -5.4% | — | — | |
| Q2 2011 | -0.3% | — | — | |
| Q1 2011 | -0.3% | — | — | |
| Q3 2010 | -2.0% | — | — | |
| Q2 2010 | +4.3% | — | — | |
| Q1 2010 | +4.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro